ヘモグロビン異常症市場：適応症、治療、診断、エンドユーザー別-2025-2030年の世界予測

ヘモグロビン異常症市場は、2023年に26億3,000万米ドルと評価され、2024年には27億9,000万米ドルに達すると予測され、CAGR 33.02％で成長し、2030年には194億6,000万米ドルに達すると予測されています。

鎌状赤血球症やサラセミアなどのヘモグロビン異常症は、赤血球中のタンパク質であるヘモグロビンに影響を及ぼす遺伝性疾患です。ヘモグロビン異常症の市場範囲は、診断薬、治療薬、支持療法を含み、患者、医療提供者、研究者にサービスを提供しています。ヘモグロビン異常症への対応の必要性は、これらの疾患に関連するかなりの罹患率と死亡率によって強調されており、早期診断、効果的な管理、定期的なモニタリングが必要とされています。治療は、遺伝子検査や輸血プロトコルから革新的な遺伝子治療や幹細胞治療まで多岐にわたる。最終用途の範囲には、主に病院、専門クリニック、遺伝性疾患に特化した研究機関が含まれます。

現在、市場成長の原動力となっているのは、遺伝子研究の進歩、患者やヘルスケア専門家の意識の高まり、新規治療のパイプラインの拡大です。注目すべきビジネスチャンスは、費用対効果の高い遺伝子検査や、CRISPRベースの遺伝子編集や低分子医薬品などの先進的な治療ソリューションの開発にあります。企業はまた、患者の転帰を改善しヘルスケアコストを削減することを目的とした個別化医療のアプローチやパートナーシップを模索すべきです。しかし、高い治療費、低所得地域におけるヘルスケアへの限られたアクセス、遺伝子研究や臨床研究に関わる複雑さなどが成長の課題となっています。また、規制上のハードルや大規模な臨床試験の必要性も、新たな治療法の開発を遅らせる要因となっています。

こうした課題を克服するため、企業は遺伝子治療とポイントオブケア診断のイノベーションに注力すべきです。バイオテクノロジー企業や学術機関との効果的なパートナーシップを構築することで、共同研究の機会を提供し、研究開発能力を高めることができます。また、ヘモグロビン異常症に関する教育を向上させるために、患者支援プログラムや啓発イニシアチブを拡大する余地もあります。市場はダイナミックであり、個別化医療や精密医療ソリューションへのシフトが進んでいるため、市場プレーヤーはこれらの動向に適応し、競争力を獲得・維持するための画期的な研究に投資することが不可欠です。

市場力学：急速に進化するヘモグロビン異常症市場の主要市場インサイトを公開

ヘモグロビン異常症市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 一般的な希少血液関連疾患の有病率の増加
  • ヘモグロビン異常症治療を求める患者数の増加
  • 新規ヘモグロビン異常症治療に対する規制機関からの承認の増加
• 市場抑制要因
  • ヘモグロビン異常症治療に伴う高コスト
• 市場機会
  • ヘモグロビン異常症治療のための継続的な研究開発活動
  • ヘモグロビン異常症治療のための新しい治療法や診断法の入手可能性
• 市場の課題
  • ヘモグロビン異常症治療に対する認識不足

ポーターのファイブフォース：ヘモグロビン異常症市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、ヘモグロビン異常症市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ヘモグロビン異常症市場における外部からの影響の把握

外部マクロ環境要因は、ヘモグロビン異常症市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ヘモグロビン異常症市場における競合情勢の把握

ヘモグロビン異常症市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスヘモグロビン異常症市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ヘモグロビン異常症市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ヘモグロビン異常症市場における成功への道筋を描く

ヘモグロビン異常症市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 一般的な稀な血液関連疾患の罹患率の増加
    • ヘモグロビン異常症治療を求める患者数の増加
    • 規制当局による新規治療法の承認増加
  • 抑制要因
    • ヘモグロビン異常症治療に伴う高コスト
  • 機会
    • ヘモグロビン異常症治療に関する進行中の研究開発活動
    • ヘモグロビン異常症治療のための新しい薬物療法と診断方法の利用可能性
  • 課題
    • ヘモグロビン異常症治療法に関する認識不足
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ヘモグロビン異常症市場適応症別

• 鎌状赤血球症
• サラセミア
  • アルファサラセミア
  • ベータサラセミア

第7章 ヘモグロビン異常症市場治療別

• 輸血
• 骨髄および幹細胞移植
• 化学療法
• 治療療法
• 遺伝子治療
• ヒドロキシウレア
• 鉄キレート療法

第8章 ヘモグロビン異常症市場診断別

• 遺伝子検査
• ヘモグロビン等電点電気泳動（Hb IEF）
• ヘモグロビン溶解度試験
• 高速液体クロマトグラフィーによるヘモグロビン
• ヘモグロビン電気泳動（Hb ELP）
• 定期的な赤血球数（RBC）測定

第9章 ヘモグロビン異常症市場：エンドユーザー別

• クリニック
• 診断検査室
• 病院

第10章 南北アメリカのヘモグロビン異常症市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のヘモグロビン異常症市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのヘモグロビン異常症市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Alnylam Pharmaceuticals, Inc.
• Bio-Rad Laboratories Inc.
• Biogen Inc.
• Bluebird Bio, Inc.
• Bristol Myers Squibb
• CRISPR Therapeutics AG
• Danaher Corporation
• Emmaus Life Sciences Inc.
• Gamida Cell Ltd.
• Genetix Biotech Asia Pvt. Ltd
• Laboratory Corporation
• Medunik USA Inc.
• Merck & Co. Inc.
• Nexcelom Bioscience LLC
• Novartis AG
• PerkinElmer Inc.
• Pfizer, Inc.
• Prolong Pharmaceuticals, LLC
• Regenacy Pharmaceuticals, Inc.
• Sangamo Therapeutics, Inc.
• Sanofi S.A.
• Sebia
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd
• Sysmex Corporation
• Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

• FIGURE 1. HEMOGLOBINOPATHIES MARKET RESEARCH PROCESS
• FIGURE 2. HEMOGLOBINOPATHIES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. HEMOGLOBINOPATHIES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. HEMOGLOBINOPATHIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HEMOGLOBINOPATHIES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HEMOGLOBINOPATHIES MARKET DYNAMICS
• TABLE 7. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY ALPHA THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY BETA THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY BONE MARROW & STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY CURATIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HYDROXYUREA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY IRON CHELATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HAEMOGLOBIN ISOELECTRIC FOCUSING (HB IEF), BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HAEMOGLOBIN SOLUBILITY TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HEMOGLOBIN BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS (HB ELP), BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY ROUTINE RED BLOOD CELL (RBC) COUNT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 50. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 51. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 52. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 77. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 78. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 79. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 82. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 83. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 84. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 89. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 94. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 99. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 104. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 109. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 114. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 119. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 124. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 129. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 140. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 145. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 150. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 155. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 160. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 165. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 167. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 168. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 169. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 170. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 175. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 180. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 185. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 187. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 188. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 189. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 190. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 191. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 193. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 194. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 195. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 200. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 205. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 215. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 220. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 225. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 230. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 235. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 240. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 241. HEMOGLOBINOPATHIES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 242. HEMOGLOBINOPATHIES MARKET, FPNV POSITIONING MATRIX, 2023

The Hemoglobinopathies Market was valued at USD 2.63 billion in 2023, expected to reach USD 2.79 billion in 2024, and is projected to grow at a CAGR of 33.02%, to USD 19.46 billion by 2030.

Hemoglobinopathies, such as sickle cell disease and thalassemia, are genetic disorders affecting hemoglobin, the protein in red blood cells. The scope of the market for hemoglobinopathies encompasses diagnostics, therapeutics, and supportive care, serving patients, healthcare providers, and researchers. The necessity of addressing hemoglobinopathies is underscored by the considerable morbidity and mortality rates associated with these conditions, necessitating early diagnosis, effective management, and periodic monitoring. Applications range from genetic testing and blood transfusion protocols to innovative gene therapies and stem cell treatments. The end-use scope primarily involves hospitals, specialty clinics, and research institutes focused on genetic disorders.

Currently, market growth is being fueled by advances in genetic research, rising awareness among patients and healthcare professionals, and the expanding pipeline of novel therapies. Notable opportunities lie in developing cost-effective genetic tests and advanced therapeutic solutions such as CRISPR-based gene editing and small molecule drugs. Companies should also explore personalized medicine approaches and partnerships aimed at improving patient outcomes and reducing healthcare costs. However, growth is challenged by high treatment costs, limited access to healthcare in low-income regions, and the complexities involved in genetic and clinical research. Regulatory hurdles and the need for extensive clinical trials can also slow the development of new treatments.

To overcome these challenges, companies should focus on innovations in gene therapy and point-of-care diagnostics. Developing effective partnerships with biotechnological firms and academic institutions can provide collaborative research opportunities and enhance R&D capabilities. There is also scope for expanding patient support programs and awareness initiatives to improve education around hemoglobinopathies. The market is dynamic, with a shift towards personalized and precision medicine solutions, making it imperative for market players to adapt and invest in groundbreaking research that aligns with these trends to capture and sustain a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hemoglobinopathies Market

The Hemoglobinopathies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of common rare blood-related diseases
  • Rising numbers of patients seeking hemoglobinopathies treatments
  • Increasing approvals from the regulatory bodies for novel hemoglobinopathies therapies
• Market Restraints
  • High cost associated with hemoglobinopathies treatment
• Market Opportunities
  • Ongoing R&D activities for the hemoglobinopathies treatment
  • Availability of new medicinal therapies and diagnostic methods for hemoglobinopathies treatment
• Market Challenges
  • Lack of awareness about hemoglobinopathies therapies

Porter's Five Forces: A Strategic Tool for Navigating the Hemoglobinopathies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hemoglobinopathies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hemoglobinopathies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hemoglobinopathies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hemoglobinopathies Market

A detailed market share analysis in the Hemoglobinopathies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hemoglobinopathies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hemoglobinopathies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hemoglobinopathies Market

A strategic analysis of the Hemoglobinopathies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hemoglobinopathies Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alnylam Pharmaceuticals, Inc., Bio-Rad Laboratories Inc., Biogen Inc., Bluebird Bio, Inc., Bristol Myers Squibb, CRISPR Therapeutics AG, Danaher Corporation, Emmaus Life Sciences Inc., Gamida Cell Ltd., Genetix Biotech Asia Pvt. Ltd, Laboratory Corporation, Medunik USA Inc., Merck & Co. Inc., Nexcelom Bioscience LLC, Novartis AG, PerkinElmer Inc., Pfizer, Inc., Prolong Pharmaceuticals, LLC, Regenacy Pharmaceuticals, Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Sebia, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Sysmex Corporation, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Hemoglobinopathies Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Indication, market is studied across Sickle Cell Disease and Thalassemia. The Thalassemia is further studied across Alpha Thalassemia and Beta thalassemia.
• Based on Treatment, market is studied across Blood Transfusion, Bone Marrow & Stem Cell Transplant, Chemotherapy, Curative Therapy, Gene Therapy, Hydroxyurea, and Iron Chelation Therapy.
• Based on Diagnosis, market is studied across Genetic Testing, Haemoglobin Isoelectric Focusing (Hb IEF), Haemoglobin Solubility Test, Hemoglobin by High Performance Liquid Chromatography, Hemoglobin electrophoresis (Hb ELP), and Routine Red Blood Cell (RBC) Count.
• Based on End-User, market is studied across Clinics, Diagnostic Laboratories, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of common rare blood-related diseases
    • 5.1.1.2. Rising numbers of patients seeking hemoglobinopathies treatments
    • 5.1.1.3. Increasing approvals from the regulatory bodies for novel hemoglobinopathies therapies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with hemoglobinopathies treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing R&D activities for the hemoglobinopathies treatment
    • 5.1.3.2. Availability of new medicinal therapies and diagnostic methods for hemoglobinopathies treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of awareness about hemoglobinopathies therapies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Hemoglobinopathies Market, by Indication

• 6.1. Introduction
• 6.2. Sickle Cell Disease
• 6.3. Thalassemia
  • 6.3.1. Alpha Thalassemia
  • 6.3.2. Beta thalassemia

7. Hemoglobinopathies Market, by Treatment

• 7.1. Introduction
• 7.2. Blood Transfusion
• 7.3. Bone Marrow & Stem Cell Transplant
• 7.4. Chemotherapy
• 7.5. Curative Therapy
• 7.6. Gene Therapy
• 7.7. Hydroxyurea
• 7.8. Iron Chelation Therapy

8. Hemoglobinopathies Market, by Diagnosis

• 8.1. Introduction
• 8.2. Genetic Testing
• 8.3. Haemoglobin Isoelectric Focusing (Hb IEF)
• 8.4. Haemoglobin Solubility Test
• 8.5. Hemoglobin by High Performance Liquid Chromatography
• 8.6. Hemoglobin electrophoresis (Hb ELP)
• 8.7. Routine Red Blood Cell (RBC) Count

9. Hemoglobinopathies Market, by End-User

• 9.1. Introduction
• 9.2. Clinics
• 9.3. Diagnostic Laboratories
• 9.4. Hospitals

10. Americas Hemoglobinopathies Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Hemoglobinopathies Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Hemoglobinopathies Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Alnylam Pharmaceuticals, Inc.
• 3. Bio-Rad Laboratories Inc.
• 4. Biogen Inc.
• 5. Bluebird Bio, Inc.
• 6. Bristol Myers Squibb
• 7. CRISPR Therapeutics AG
• 8. Danaher Corporation
• 9. Emmaus Life Sciences Inc.
• 10. Gamida Cell Ltd.
• 11. Genetix Biotech Asia Pvt. Ltd
• 12. Laboratory Corporation
• 13. Medunik USA Inc.
• 14. Merck & Co. Inc.
• 15. Nexcelom Bioscience LLC
• 16. Novartis AG
• 17. PerkinElmer Inc.
• 18. Pfizer, Inc.
• 19. Prolong Pharmaceuticals, LLC
• 20. Regenacy Pharmaceuticals, Inc.
• 21. Sangamo Therapeutics, Inc.
• 22. Sanofi S.A.
• 23. Sebia
• 24. Shenzhen Mindray Bio-Medical Electronics Co., Ltd
• 25. Sysmex Corporation
• 26. Vertex Pharmaceuticals Incorporated